QIAGEN Expands Master Collaboration Agreement With AstraZeneca's Future Therapies To Develop And Validate A Genotyping Assay Using Co's Syndromic Testing Platform QIAstat-Dx
QIAGEN Expands Master Collaboration Agreement With AstraZeneca's Future Therapies To Develop And Validate A Genotyping Assay Using Co's Syndromic Testing Platform QIAstat-Dx
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))))) today announced the expansion of its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics (CDx) for AstraZeneca's future therapies being developed to address chronic diseases.
Qiagen（紐交所：QGEN，法蘭克福證券交易所：QIA）今天宣佈，將擴大與阿斯利康的主要合作協議，共同開發和商業化阿斯利康未來用於治療慢性疾病的伴隨診斷（CDx）。
Under the agreement, QIAGEN will develop and validate a genotyping assay using QIAGEN's syndromic testing platform QIAstat-Dx. The test will enable specialty care providers to potentially perform genotyping whilst patients are undergoing routine clinical examination, thus enabling fast decision making for potential suitability for AstraZeneca's genomically targeted medicines.
根據協議，Qiagen將利用Qiagen的綜合測試平台QIAstat-Dx開發和驗證一種基因型鑑定測定方法。該測定方法將使專科醫療提供者能夠在患者進行常規臨床檢查時進行基因型鑑定，從而能夠快速決策是否適合使用阿斯利康的基因組靶向藥物。
譯文內容由第三人軟體翻譯。